Inhibitor timidilatne sintaze
Inhibitori timidilatne sintaze su hemijski agensi koji inhibiraju enzim timidilatna sintaza, te mogu da nađu primenu u antikancernoj hemoterapiji.[1] Pet agenasa je bilo u kliničkim israživanjima 2002: raltitreksed, pemetreksed, nolatreksed, ZD9331, i GS7904L.[2]
Primeri lekova ove klase su:
- Raltitreksed, koristi se za kolorektalni kancer od 1998
- Fluorouracil, koristi se za kolorektalni kancer[3]
- BGC 945[4]
- OSI-7904L[5]
Reference
- ↑ Jackman, A.L.; Calvert, A.H. (1995). „Folate-based thymidylate synthase inhibitors as anticancer drugs”. Annals of Oncology 6 (9): 871–881.
- ↑ „Thymidylate synthase inhibitors as anticancer agents: from bench to bedside”. Pristupljeno 2009-01-28.
- ↑ Papamichael, D. (1999). „The use of thymidylate synthase inhibitors in the treatment of advanced colorectal cancer: current status”. Oncologist 4 (6): 478–87. PMID 10631692. [mrtav link]
- ↑ Gibbs, David D., et al (2005). „BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to α-folate receptor-overexpressing tumors”. Cancer Research 65 (24): 11721–11728. DOI:10.1158/0008-5472.CAN-05-2034.
- ↑ Ricart AD, Berlin JD, Papadopoulos KP, et al. (December 2008). „Phase I, pharmacokinetic and biological correlative study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor, and cisplatin in patients with solid tumors”. Clin. Cancer Res. 14 (23): 7947–55. DOI:10.1158/1078-0432.CCR-08-0864. PMID 19047127.
- p
- r
- u
Intracelularni hemoterapijski lekovi/Antineoplastični lekovi (L01)
(M faza)
Blokiranje formiranja microtubule | |
---|---|
Blokiranje rasformiranja microtubule |
DNK replikacije
| |||||||||
|
FI (Tipifarnib) • CDK inhibitori (Alvocidib, Seliciklib) • PrI (Bortezomib) • PhI (Anagrelid) • IMPDI (Tiazofurin) • LI (Masoprokol) • PARP inhibitor (Olaparib) • HDAC (Vorinostat, Romidepsin) | |
Receptorski antagonisti | |
Drugi/negrupisani | Amsakrin • Trabektedin • retinoidi (Alitretinoin, Tretinoin) • Arsen trioksid • asparaginski iscrpljivači (Asparaginaza/Pegaspargaza) • Celekoksib • Demekolcin • Elesklomol • Elsamitrucin • Etoglucid • Lonidamin • Lukanton • Mitoguazon • Mitotan • Oblimersen • mTOR inhibitori (Everolimus, Temsirolimus) |